Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse events.
- DOI
- 10.1016/j.ijbiomac.2026.151096
- Published
- 2026 Mar
- Container
- International journal of biological macromolecules
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ijbiomac.2026.151096,
title = {Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse events.},
author = {Huang BC and Hong ST and Liao TY and Ho KW and Liao JM and Hsieh YC and Cheng YA and Liu ES and Li CC and Li PJ and Chen FM and Chen CY and Cheng TL and Huang MY and Chuang CH},
year = {2026},
journal = {International journal of biological macromolecules},
doi = {10.1016/j.ijbiomac.2026.151096},
url = {https://doi.org/10.1016/j.ijbiomac.2026.151096}
}RIS
TY - JOUR TI - Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse events. AU - Huang BC AU - Hong ST AU - Liao TY AU - Ho KW AU - Liao JM AU - Hsieh YC AU - Cheng YA AU - Liu ES AU - Li CC AU - Li PJ AU - Chen FM AU - Chen CY AU - Cheng TL AU - Huang MY AU - Chuang CH PY - 2026 JO - International journal of biological macromolecules DO - 10.1016/j.ijbiomac.2026.151096 UR - https://doi.org/10.1016/j.ijbiomac.2026.151096 ER -
APA
BC, H., ST, H., TY, L., KW, H., JM, L., YC, H., YA, C., ES, L., CC, L., PJ, L., FM, C., CY, C., TL, C., MY, H., & CH, C. (2026). Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse events.. International journal of biological macromolecules. https://doi.org/10.1016/j.ijbiomac.2026.151096
Source records
- pubmed · retrieved 2026-09-26T12:59:16.767Z